Sparks

Tissue Regenix (LSE: TRX) announces H124 results

Tissue Regenix’s H124 results reflect sustained progress across its multiple areas of business, with revenues increasing by 16% to US$16.4m (H123: US$14.1m). This was largely driven by the robust performance of its key technology platforms, BioRinse (sales up by 12% to US$10.5m; H123: US$9.4m) and dCELL (sales up by 34% to US$4.2m; H123: US$3.1m). Gross profit also increased to 53% (H123: 49%) due to greater processing efficiencies and a favourable product mix. The company ended the period with a cash position of US$3.5m, which should see it through current business plans, including the Phase 2 capacity expansion of its San Antonio facility, expected to complete in 2025. Collectively, these results mark Tissue Regenix’s eighth consecutive period of growth and the seventh consecutive period of double-digit, half-on-half growth.

Next Sparks Commentary in this sector >

Latest

Consumer | Comment

22.11.24

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Equities

Equities by Sector

Sectors

Thematics

Latest

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

Audiovisual

Latest

Recce Pharmaceuticals – executive interview

VEON – executive interview with CFO Joop Brakenhoff

VEON – executive interview with CEO Kaan Terzioğlu

About Edison

About Edison

Careers

Sparks

Latest

The Platform Group (FRA: TPG) – Strong growth in Q324

Games Workshop (LSE: GAW) significant growth in H125 trading update

PVA TePla (FRA: TPE) initiates share buyback programme

Renold (LSE: RNO) – Solid first half results

Revolution Beauty (LSE: REVB) – H125 results weak due to simplification of portfolio

Subscribe to Edison